International Journal of Medical and Pharmaceutical Research

Online ISSN-2958-3683 | Print ISSN-2958-3675
Frequency: Bi-Monthly
Available online on: https://ijmpr.in/

Original Article

Current Treatment Paradigm and Recent Advances in Small-Cell Lung Cancer

Dr. Praloy Basu

Department of Medical Oncology Netaji Subhash Chandra Bose Cancer Hospital, Kolkata, West Bengal, India

OPEN ACCESS

Corresponding Author:

Dr. Praloy Basu
Department of Medical Oncology Netaji Subhash Chandra Bose Cancer Hospital, Kolkata, West Bengal, India

Received: 18-03-2026
Accepted: 23-04-2026
Available online: 13-05-2026

ABSTRACT

Small-cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies and continues to pose major therapeutic challenges despite decades of clinical research. Characterized by rapid doubling time, early dissemination, marked genomic instability, and almost universal relapse after initial therapy, SCLC has historically been associated with poor long-term survival outcomes. For several decades, Platinum-Etoposide chemotherapy remained the standard systemic treatment with only marginal improvements in survival. However, the therapeutic landscape of SCLC has evolved substantially during the past decade with the incorporation of immune checkpoint inhibitors, advances in radiotherapy, emergence of DLL3-targeted therapies, and increasing understanding of molecular biology and tumor heterogeneity. Chemo-immunotherapy with Atezolizumab or Durvalumab combined with Platinum-Etoposide has become the global standard first-line treatment for extensive-stage SCLC (ES-SCLC). More recently, DLL3-targeted T-cell engagers such as Tarlatamab have demonstrated clinically meaningful survival improvements in relapsed disease, representing a major breakthrough in the post-Platinum setting. Simultaneously, molecular subtype classification, circulating tumor DNA analysis, SLFN11-guided treatment strategies, and modern radiotherapy approaches including hippocampal-avoidance prophylactic cranial irradiation are contributing toward precision oncology in SCLC. This review summarizes current treatment paradigms, evolving biomarkers, recent therapeutic advances, radiotherapy developments, supportive care strategies, and future directions in both extensive-stage and limited-stage SCLC.

Keywords: Small Cell Lung Cancer, Immune Checkpoint inhibitors, Durvalumab, Atezolizumab, Precision medicine.

INTRODUCTION

Small-cell lung cancer (SCLC) accounts for approximately 13–15% of all lung cancers worldwide and remains strongly associated with chronic tobacco exposure (1). Biologically, SCLC is characterized by rapid tumor doubling time, high proliferative activity, neuroendocrine differentiation, early metastatic dissemination, and profound genomic instability. Compared with non-small-cell lung cancer (NSCLC), SCLC demonstrates significantly more aggressive clinical behavior and substantially worse long-term outcomes.

At diagnosis, nearly two-thirds of patients present with extensive-stage disease involving distant metastases. Common sites of metastasis include the liver, brain, bone marrow, adrenal glands, and bone. Untreated SCLC has a median survival of only 2–4 months. Historically, even with treatment, median overall survival (OS) remained approximately 8–10 months for extensive-stage disease and 15–20 months for limited-stage disease (2).

For more than three decades, Platinum-Etoposide chemotherapy remained the standard first-line treatment. Although objective response rates exceeded 60–70%, most patients relapsed within months because of rapid emergence of therapeutic resistance. Consequently, durable survival remained uncommon.

The therapeutic landscape has changed significantly during the past decade. The addition of immune checkpoint inhibitors to Platinum-based chemotherapy resulted in modest but clinically meaningful improvements in survival and established chemo-immunotherapy as the standard first-line treatment for ES-SCLC (3–6). More recently, DLL3-targeted therapies such as Tarlatamab have demonstrated survival superiority over chemotherapy in relapsed disease, representing one of the most important advances in SCLC therapeutics in decades (7,8).

Simultaneously, major advances in understanding SCLC biology have identified therapeutically relevant molecular subtypes, tumor microenvironment characteristics, DNA damage response vulnerabilities, and lineage plasticity mechanisms (9–12). These discoveries are paving the way for biomarker-driven and precision oncology approaches.

This review discusses the current treatment paradigm and recent advances in systemic therapy, radiotherapy, molecular biology, biomarkers, supportive care, and emerging therapeutic strategies in SCLC.

BIOLOGY AND GENOMIC LANDSCAPE OF SCLC

SCLC is characterized by one of the highest mutational burdens among solid tumors, largely because of chronic tobacco carcinogen exposure. Despite this elevated tumor mutational burden, durable responses to immunotherapy occur only in a minority of patients, suggesting that mutational burden alone does not adequately predict immune responsiveness.

The genomic hallmark of SCLC is near-universal inactivation of TP53 and RB1, observed in approximately 90% of tumors (9). Loss of TP53 impairs apoptosis and DNA damage repair, while RB1 inactivation disrupts cell-cycle regulation and promotes uncontrolled proliferation. Together, these alterations contribute to genomic instability, rapid growth kinetics, and therapeutic resistance.

Additional recurrent molecular abnormalities include MYC amplification, PTEN loss, CREBBP mutations, EP300 alterations, and NOTCH pathway dysregulation. These molecular events contribute to tumor progression, lineage plasticity, neuroendocrine differentiation, and immune evasion.

A particularly important feature of SCLC biology is intratumoral heterogeneity and lineage plasticity. Under therapeutic pressure, tumors may transition between neuroendocrine and non-neuroendocrine states, facilitating acquired resistance. This partially explains the transient nature of responses to chemotherapy and immunotherapy.

Another hallmark of SCLC biology is replication stress resulting from rapid proliferation and defective DNA repair mechanisms. This creates therapeutic vulnerabilities involving PARP, ATR, CHK1, WEE1, and DNA-PK pathways.

MOLECULAR SUBTYPES OF SCLC

Recent transcriptomic analyses have identified four major molecular subtypes of SCLC based on dominant transcription factor expression (10,11).

(a) SCLC-A (ASCL1 Dominant)

SCLC-A represents the classical neuroendocrine subtype and is characterized by high ASCL1 expression, elevated DLL3 expression, and BCL2 overexpression. This subtype demonstrates classical neuroendocrine morphology and may be particularly susceptible to DLL3-targeted therapies and BCL2 inhibition.

(b) SCLC-N (NEUROD1 Dominant)

The SCLC-N subtype demonstrates NEUROD1 expression and MYC-driven biology. These tumors often exhibit aggressive metastatic behavior and relative resistance to standard therapy. Potential therapeutic vulnerabilities include Aurora kinase inhibitors and DNA damage response-targeted agents.

(c) SCLC-P (POU2F3 Dominant)

This subtype exhibits tuft-cell lineage characteristics and reduced neuroendocrine differentiation. It represents a biologically distinct subgroup with potentially unique therapeutic vulnerabilities.

(d) SCLC-I (Inflammatory Subtype)

The inflammatory subtype demonstrates increased immune infiltration, interferon signaling, inflamed tumor microenvironment characteristics, and reduced neuroendocrine differentiation. Emerging evidence suggests this subtype may derive greater benefit from immune checkpoint inhibition.

Although these molecular classifications are not yet routinely used in clinical decision-making, they are increasingly important in translational research and may eventually guide biomarker-driven therapy selection.

TUMOR MICROENVIRONMENT AND IMMUNE EVASION

The SCLC tumor microenvironment is generally highly immunosuppressive. Tumors demonstrate low expression of major histocompatibility complex class I molecules, impaired antigen presentation, exclusion of cytotoxic T lymphocytes, and infiltration by immunosuppressive cell populations such as regulatory T cells and myeloid-derived suppressor cells (12). Expression of inhibitory immune checkpoints including TIGIT, TIM-3, and LAG-3 further contributes to immune evasion and provides rationale for novel immunotherapeutic combinations targeting pathways beyond PD-1/PD-L1.

Additionally, angiogenesis plays an important role in SCLC progression. Vascular endothelial growth factor (VEGF) expression is frequently elevated and contributes to tumor growth, vascular permeability, and metastatic dissemination. Anti-angiogenic approaches have therefore been explored in combination with chemotherapy and immunotherapy, although definitive survival benefits remain limited.

Cancer-associated fibroblasts, macrophages, and inflammatory cytokines also contribute to tumor progression and resistance mechanisms. Increasing understanding of the tumor microenvironment is expected to facilitate development of more effective combination immunotherapy strategies.

FIRST-LINE THERAPY IN EXTENSIVE-STAGE SCLC

(A) Historical Standard: Platinum-Etoposide Chemotherapy

Before the immunotherapy era, Platinum-Etoposide chemotherapy represented the standard first-line treatment for ES-SCLC for more than 30 years. Cisplatin or Carboplatin combined with Etoposide produced high initial response rates approaching 60–70%. However, progression-free survival remained short and nearly all patients eventually relapsed.

Carboplatin has become increasingly favored over Cisplatin in routine practice because of lower nephrotoxicity, reduced emesis, better tolerability, and easier outpatient administration. Particularly in elderly patients and those with poor performance status, Carboplatin-based therapy is often preferred.

Although response rates to chemotherapy are high, relapse almost invariably occurs because residual tumor clones rapidly acquire resistance through multiple molecular mechanisms including lineage plasticity, altered apoptotic signaling, and enhanced DNA repair.

(B) CHEMO-IMMUNOTHERAPY AS THE STANDARD OF CARE

(a) IMpower133 Trial

The phase III IMpower133 trial represented the first positive immunotherapy trial in ES-SCLC and fundamentally changed the treatment landscape (3). Prior to this study, multiple immunotherapeutic approaches in SCLC had failed to demonstrate meaningful survival improvements, and Platinum-Etoposide chemotherapy remained unchanged for decades.

IMpower133 randomized treatment-naïve ES-SCLC patients to receive Carboplatin-Etoposide with either Atezolizumab or placebo for four induction cycles followed by maintenance Atezolizumab or placebo. The study included patients with treated asymptomatic brain metastases and ECOG performance status 0–1.

Median overall survival improved from 10.3 months to 12.3 months, while progression-free survival improved from 4.3 months to 5.2 months. Importantly, landmark survival analyses demonstrated persistent separation of survival curves and durable benefit in a subset of patients (4). The hazard ratio for death was 0.70, representing a clinically meaningful reduction in mortality risk.

Objective response rates were similar between treatment groups, highlighting that the major contribution of immunotherapy was prolongation of response durability rather than increased initial tumor shrinkage. Duration of response was longer with Atezolizumab-containing therapy, and a subset of patients experienced prolonged disease control exceeding two years.

Long-term follow-up from IMpower133 was particularly important because it demonstrated a sustained tail on the survival curve, with approximately 12% of patients alive at 5 years. This represented one of the first indications that durable long-term survival could be achieved in selected ES-SCLC patients treated with immunotherapy.

Subgroup analyses suggested benefit across most clinical subsets including patients with liver metastases, although outcomes remained poorer in patients with high metastatic burden and poor performance status. Importantly, PD-L1 expression and tumor mutational burden were not consistently predictive of benefit.

The toxicity profile was generally manageable. Immune-related adverse events including rash, hepatitis, hypothyroidism, and pneumonitis occurred infrequently and were usually manageable with standard immunosuppressive approaches. Rates of treatment discontinuation because of adverse events remained acceptable.

IMpower133 established chemo-immunotherapy as the global standard first-line treatment for ES-SCLC and demonstrated that immune checkpoint inhibition could meaningfully improve survival in this disease.

(b) CASPIAN Trial

The phase III CASPIAN trial further established chemo-immunotherapy as the standard first-line treatment for ES-SCLC (5). The study evaluated Durvalumab plus Platinum-Etoposide compared with Platinum-Etoposide chemotherapy alone. A third arm evaluating Durvalumab combined with Tremelimumab plus chemotherapy was also included.

One of the major strengths of CASPIAN was its pragmatic design. Unlike IMpower133, the trial allowed investigator choice of either Cisplatin or Carboplatin, thereby increasing applicability to routine clinical practice. In addition, up to six cycles of chemotherapy were permitted in the control arm, reflecting real-world management patterns.

Median overall survival improved to 13.0 months in the Durvalumab arm compared with 10.3 months with chemotherapy alone. The hazard ratio for death was 0.73, confirming a significant survival advantage with chemo-immunotherapy.

Importantly, updated analyses demonstrated sustained long-term benefit, with approximately 18% of patients alive at 3 years in the Durvalumab arm compared with only 5–6% in the chemotherapy-alone group (6). This reinforced the concept that immunotherapy can produce durable disease control in a subset of ES-SCLC patients.

Benefits were observed across most predefined clinical subgroups including age, sex, smoking status, and presence of brain or liver metastases. Similar to IMpower133, no robust predictive biomarker for benefit could be identified.

The CASPIAN trial also provided important insights into treatment tolerability. Rates of grade 3 or higher adverse events were comparable between treatment groups. Immune-related toxicities including thyroid dysfunction, pneumonitis, dermatitis, and hepatitis were generally manageable with established treatment protocols.

The Tremelimumab-containing arm failed to demonstrate meaningful survival improvement while increasing treatment-related toxicity (13). Consequently, routine CTLA-4 blockade has not become part of standard therapy in ES-SCLC.

Together, IMpower133 and CASPIAN firmly established PD-L1 inhibitor-based chemo-immunotherapy as the international standard first-line treatment approach in ES-SCLC.

(c) PRACTICAL CONSIDERATIONS IN FIRST-LINE MANAGEMENT

Choice between Atezolizumab-based and Durvalumab-based regimens is generally influenced by institutional preference, availability, reimbursement, and physician familiarity because direct comparative studies are lacking.

Several clinical factors influence prognosis despite chemo-immunotherapy, including poor performance status, extensive liver metastases, elevated lactate dehydrogenase levels, significant weight loss, and high metastatic burden.

Patients with untreated brain metastases often require individualized treatment planning involving integration of systemic therapy and radiotherapy. Elderly patients and those with comorbidities may still derive benefit from chemo-immunotherapy with appropriate toxicity monitoring.

Real-world studies have validated efficacy and tolerability of chemo-immunotherapy combinations outside clinical trials, although outcomes remain poorer in frail patients.

Immune-related adverse events including pneumonitis, hepatitis, colitis, thyroid dysfunction, adrenal insufficiency, and dermatologic toxicities require prompt recognition and multidisciplinary management.

(d) BIOMARKERS IN FIRST-LINE THERAPY

At present, no validated predictive biomarker reliably identifies patients most likely to benefit from immune checkpoint inhibition in SCLC.

PD-L1 expression demonstrates limited predictive utility because of low expression levels, tumor heterogeneity, and dynamic expression changes. Tumor mutational burden has also shown inconsistent predictive value in prospective studies. Emerging evidence suggests that inflammatory SCLC-I tumors may derive greater benefit from immunotherapy because of enhanced immune infiltration and interferon signaling.

Circulating tumor DNA kinetics are also being investigated as dynamic biomarkers of treatment response and early relapse prediction. Rapid decline in ctDNA levels during treatment may correlate with improved outcomes.
Other emerging biomarkers under investigation include:

- SLFN11 expression
- DLL3 expression
- Tumor-infiltrating lymphocyte density
- Gene expression signatures
- Neuroendocrine differentiation markers

RADIOTHERAPY IN SCLC

(a) CONCURRENT CHEMORADIOTHERAPY IN LIMITED-STAGE DISEASE

Concurrent chemoradiotherapy remains the cornerstone of treatment for limited-stage SCLC and offers the best opportunity for cure.

Early thoracic radiotherapy initiation during the first or second chemotherapy cycle is associated with superior outcomes. Hyperfractionated twice-daily thoracic radiotherapy demonstrated survival advantages in randomized studies, although once-daily regimens remain widely used because of convenience and improved tolerability (14).

Modern radiotherapy techniques including intensity-modulated radiotherapy, image-guided radiotherapy, and volumetric arc therapy have improved precision while reducing exposure to surrounding normal tissues.

Optimal radiation dose, fractionation schedules, and integration with immunotherapy continue to be areas of ongoing research.

(b) CONSOLIDATIVE THORACIC RADIOTHERAPY IN ES-SCLC

The CREST trial demonstrated that consolidative thoracic radiotherapy improved intrathoracic control and long-term survival in patients with ES-SCLC who responded to chemotherapy but retained residual thoracic disease (15).

Although randomized evidence in the chemo-immunotherapy era remains limited, thoracic radiotherapy continues to be considered in selected responders with persistent thoracic disease after systemic therapy.

Potential benefits of consolidative thoracic radiotherapy include improved local control, delayed thoracic progression, and possible enhancement of systemic immune responses through antigen release and immunogenic cell death.

Optimal patient selection, timing, radiation dose, and integration with immunotherapy remain areas of active investigation.

(c) PROPHYLACTIC CRANIAL IRRADIATION

Brain metastases are highly prevalent in SCLC because of the neurotropic nature of the disease. Historically, prophylactic cranial irradiation (PCI) reduced intracranial relapse and improved survival in selected patients.

However, the Japanese randomized trial comparing PCI with MRI surveillance demonstrated no significant overall survival advantage for PCI in ES-SCLC despite lower rates of brain metastases (16). Consequently, MRI surveillance has become increasingly accepted in centers with access to high-quality neuroimaging.

In limited-stage disease, PCI continues to play an important role, particularly in patients achieving good response after chemoradiotherapy.

(d) HIPPOCAMPAL-AVOIDANCE PCI

Neurocognitive toxicity remains a major limitation of PCI. Hippocampal-avoidance PCI significantly reduces memory impairment and cognitive decline while maintaining intracranial disease control (17).

Modern planning techniques have facilitated increasing adoption of hippocampal-sparing approaches in contemporary practice.
Additional strategies to reduce neurotoxicity include:

- Memantine administration
- Improved MRI surveillance
- Individualized patient selection

These approaches aim to preserve quality of life while maintaining intracranial disease control.

RELAPSED AND REFRACTORY SCLC

Relapsed SCLC remains one of the greatest therapeutic challenges in thoracic oncology. Patients are generally classified as Platinum-sensitive relapse or Platinum-resistant relapse based on interval from completion of first-line therapy.

Platinum-sensitive relapse, generally defined as recurrence more than 90 days after treatment completion, is associated with higher response rates and improved outcomes.

By contrast, Platinum-resistant relapse is associated with poor prognosis, low response rates, and limited treatment options. Median survival after relapse remains poor, highlighting the need for more effective therapies.

(a) TOPOTECAN AND CYTOTOXIC CHEMOTHERAPY

Topotecan historically represented the only approved second-line therapy for relapsed SCLC. Both oral and intravenous formulations demonstrated modest response rates and median survival of approximately six months (18).
However, hematologic toxicity including neutropenia, thrombocytopenia, and anemia frequently limits tolerability.

Other cytotoxic options include Temozolomide, irinotecan, paclitaxel, and gemcitabine. Temozolomide may be particularly useful in patients with brain metastases because of central nervous system penetration.

Platinum rechallenge remains appropriate in carefully selected Platinum-sensitive patients.

Despite these options, outcomes with conventional chemotherapy remain disappointing, underscoring the need for novel therapeutic approaches.

(b) LURBINECTEDIN

Lurbinectedin received accelerated approval following phase II data demonstrating response rates of approximately 35% in relapsed SCLC (19).

The drug inhibits oncogenic transcription and promotes apoptosis. Although the randomized ATLANTIS trial failed to demonstrate superior overall survival compared with standard chemotherapy, Lurbinectedin remains clinically useful because of favorable toxicity profile, outpatient feasibility, and meaningful activity in selected patients.
Common toxicities include:

- Myelosuppression
- Fatigue
- Nausea
- Elevated liver enzymes

Real-world evidence continues to support its role in relapsed disease (20).

(c) DLL3-TARGETED THERAPIES

DLL3 is highly expressed on SCLC cells while minimally expressed in normal tissues, making it an attractive therapeutic target.
DLL3-targeted therapeutic approaches include:

- T-cell engagers
- Antibody-drug conjugates
- CAR-T therapy
- CAR-NK therapy
- Radiotheranostics

DLL3-directed imaging approaches may also facilitate non-invasive assessment of target expression.

(d) TARLATAMAB

Tarlatamab is a DLL3-CD3 bispecific T-cell engager that redirects cytotoxic T cells toward DLL3-expressing tumor cells. The phase II DeLLphi-301 trial demonstrated promising response rates and durable activity in heavily pretreated SCLC (7). Subsequently, the phase III DeLLphi-304 trial demonstrated superior overall survival compared with physician's-choice chemotherapy, representing the first therapy to improve survival beyond chemotherapy in relapsed SCLC (8).
Median overall survival exceeded 13 months, and patient-reported outcomes favored Tarlatamab.
This represents one of the most important therapeutic advances in SCLC in recent decades.
The durability of response observed with Tarlatamab has generated substantial enthusiasm regarding DLL3-targeted immunotherapy strategies.

Toxicities of T-Cell Engagers
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are characteristic toxicities associated with T-cell engager therapy.

Most CRS events occur early during treatment initiation and are generally low grade.
Standard management includes:

- Step-up dosing
- Premedication
- Tocilizumab administration
- Corticosteroids
- Early inpatient monitoring

Structured toxicity management protocols are essential for safe administration.
Education of healthcare teams and patients regarding early symptom recognition is critical.

(e) DNA DAMAGE RESPONSE TARGETING

Profound genomic instability and replication stress provide rationale for DNA damage response-targeted therapy in SCLC.

(i) PARP Inhibitors

PARP inhibitors combined with Temozolomide have demonstrated encouraging activity, particularly in SLFN11-positive tumors (21,22).

Potential mechanisms include impaired DNA repair and enhanced sensitivity to DNA-damaging agents.

(ii) ATR Inhibitors

ATR inhibition has also been investigated extensively. However, randomized studies evaluating berzosertib combined with Topotecan failed to demonstrate significant progression-free survival benefit (23).

(iii) Additional investigational approaches include:

- WEE1 inhibition
- CHK1 targeting
- DNA-PK inhibition

Biomarker-driven patient selection may improve outcomes with these strategies.

SUPPORTIVE CARE AND QUALITY OF LIFE

(a) Trilaciclib and Myelopreservation

Chemotherapy-induced myelosuppression remains a major challenge in SCLC management. Trilaciclib has demonstrated reduction in severe neutropenia, transfusion requirements, and G-CSF use while preserving treatment efficacy (24,25).

(b) Symptom Management

Patients frequently experience severe symptom burden including:

- Dyspnea
- Fatigue
- Cachexia
- Pain
- Neurologic complications

Early palliative care integration significantly improves symptom control and quality of life.

Smoking cessation remains critically important because continued smoking negatively impacts treatment outcomes and pulmonary function.

Nutritional support, psychosocial care, pulmonary rehabilitation, and management of treatment-related toxicities are also essential components of comprehensive SCLC care.

LIMITED-STAGE SCLC AND CONSOLIDATION IMMUNOTHERAPY

Historically, treatment advances in limited-stage SCLC were largely confined to optimization of chemoradiotherapy and radiotherapy techniques. Despite aggressive multimodality treatment, relapse rates remained high and long-term survival outcomes remained suboptimal.

The ADRIATIC trial therefore represented a landmark development in LS-SCLC management. This phase III randomized study evaluated consolidation Durvalumab following concurrent chemoradiotherapy in patients with limited-stage SCLC who had not experienced disease progression after definitive treatment (26).

Patients were randomized to receive Durvalumab, Durvalumab plus tremelimumab, or placebo following completion of concurrent Platinum-based chemoradiotherapy. The rationale for the study was based on the hypothesis that chemoradiotherapy could enhance antigen presentation and immune priming, thereby improving responsiveness to immune checkpoint inhibition.

ADRIATIC demonstrated significant improvements in both progression-free survival and overall survival with consolidation Durvalumab compared with placebo. Median progression-free survival was substantially prolonged, and overall survival analyses demonstrated clinically meaningful reduction in mortality risk.

Importantly, the survival benefit appeared durable and was accompanied by acceptable toxicity. Although immune-related adverse events including pneumonitis remain important concerns in the post-radiotherapy setting, overall tolerability was manageable with standard monitoring and treatment protocols.

The study established consolidation Durvalumab as a new standard of care following definitive concurrent chemoradiotherapy in LS-SCLC and represented the first major therapeutic advance in this setting in several decades.

ADRIATIC also provided important proof-of-concept evidence supporting integration of immunotherapy into earlier stages of SCLC. Ongoing research is evaluating additional strategies including concurrent immunotherapy with chemoradiation, novel checkpoint inhibitor combinations, and biomarker-driven patient selection.

The success of ADRIATIC highlights the growing role of immunotherapy across the entire spectrum of SCLC management and raises the possibility of further improvements in cure rates with optimized multimodality approaches.

EMERGING THERAPEUTICS AND FUTURE DIRECTIONS

The therapeutic landscape of SCLC is evolving rapidly.

DLL3 Therapeutic Ecosystem

Beyond Tarlatamab, several DLL3-targeted approaches are under investigation including:

- Obrixtamig
- HPN328
- DLL3 antibody-drug conjugates
- DLL3 CAR-T therapy
- DLL3 CAR-NK therapy

Radiotheranostic approaches utilizing DLL3 PET imaging may facilitate non-invasive target assessment and therapeutic selection.

NOVEL IMMUNOTHERAPEUTIC TARGETS

Emerging strategies include:

- TIGIT inhibition
- TIM-3 blockade
- LAG-3 inhibition
- CD47/SIRPα targeting
- Tumor microenvironment modulation

Combination immunotherapy approaches aim to overcome resistance mechanisms and improve durability of response.
Anti-angiogenic combinations, epigenetic therapies, and tumor microenvironment-directed approaches are also being actively explored.

PRECISION ONCOLOGY IN SCLC

Precision oncology approaches are increasingly relevant despite historically limited biomarker-driven treatment options in SCLC.

Potential future biomarkers include:

- SLFN11 expression
- Molecular subtype classification
- DLL3 expression
- ctDNA kinetics
- Immune microenvironment signatures

Liquid biopsy technologies may facilitate:

- Minimal residual disease monitoring
- Early relapse detection
- Dynamic response assessment

Artificial intelligence-based radiomics may further enhance treatment personalization.

Integration of molecular profiling into clinical trials is expected to accelerate development of individualized therapeutic strategies.

CONCLUSION

SCLC has historically been associated with poor outcomes and limited therapeutic progress. However, major advances during the past decade have transformed the treatment landscape.

Chemo-immunotherapy with Atezolizumab or Durvalumab combined with Platinum-Etoposide has become the standard first-line therapy for ES-SCLC, while consolidation Durvalumab has improved outcomes in LS-SCLC. Most importantly, DLL3-targeted therapies such as Tarlatamab represent a transformative advance in relapsed disease.

Ongoing progress will likely depend upon biomarker-driven therapeutic selection, rational combination therapies, optimization of radiotherapy strategies, and development of precision oncology frameworks. Although significant challenges remain, the future of SCLC management appears more promising than at any point in recent decades.

REFERENCES

1. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-9. Doi:10.1056/NEJMoa1809064.
2. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-30. Doi:10.1200/JCO.20.01055.
3. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus Platinum–Etoposide versus Platinum–Etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-39. Doi:10.1016/S0140-6736(19)32222-6.
4. Paz-Ares L, Dvorkin M, Feltquate D, McCoy S, Özgüroğlu M, Reck M, et al. 3-year overall survival update from CASPIAN: Durvalumab plus Platinum–Etoposide vs Platinum–Etoposide in ES-SCLC. ESMO Open. 2022;7:100408. Doi:10.1016/j.esmoop.2022.100408.
5. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus Platinum–Etoposide in first-line ES-SCLC: updated results from CASPIAN. Lancet. 2021;397(10277):1920-32. Doi:10.1016/S0140-6736(21)01254-1.
6. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small-cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289-97. Doi:10.1038/s41568-019-0133-9.
7. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major SCLC subtypes. Cancer Cell. 2021;39(3):346-60.e7. doi:10.1016/j.ccell.2020.12.014.
8. Nabet BY, Gaya-Prats A, Wang S, Chabon JJ, Stevenson K, Zhou S, et al. Immune heterogeneity in small-cell lung cancer and clinical implications. Cancer Cell. 2024;42(3):198-215.e6. doi:10.1016/j.ccell.2024.02.001.
9. Park S, Lee H, Choi Y, Kim J, Cho JH, Choi CM, et al. Transcription factor-based molecular subtypes and correlation to outcomes in SCLC: a comprehensive analysis. EBioMedicine. 2024;100:105497. Doi:10.1016/j.ebiom.2024.105497.
10. Tendler S, Dunphy MP, Farwell MD, Carrasquillo JA, Gönen M, Nia E, et al. First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase ½ trial. J Nucl Med. 2024;65(5):716-23. Doi:10.2967/jnumed.123.266055.
11. Daly ME, Singh N, Ismaila N, Decker RH, Isfahanian N, Leal TA, et al. Radiation therapy for small-cell lung cancer: ASCO guideline endorsement of the ASTRO guideline. J Clin Oncol. 2021;39(8):931-9. Doi:10.1200/JCO.20.03364.
12. Ahn MJ, Cho BC, Siena S, Havel L, Lin CC, Wrona A, et al. Tarlatamab for patients with previously treated small-cell lung cancer (DeLLphi-301). N Engl J Med. 2023;389(20):1891-904. Doi:10.1056/NEJMoa2307980.
13. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive-stage small-cell lung cancer: a phase 3 randomised controlled trial (CREST). Lancet. 2015;385(9962):36-42. Doi:10.1016/S0140-6736(14)61085-0.
14. Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645-57. Doi:10.1016/S1470-2045(20)30068-1.
15. Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663-71. Doi:10.1016/S1470-2045(17)30230-9.
16. Rodríguez de Dios N, Counago F, Murcia-Mejía M, Rica R, Gómez-Caamaño A, López-Guerra JL, et al. Randomized Phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER). J Clin Oncol. 2021;39(33):3569-79. Doi:10.1200/JCO.21.00639.
17. Mountzios G, Boyle T, Paz-Ares L, Amrane K, Han JY, Remon J, et al. Tarlatamab in small-cell lung cancer after Platinum-based chemotherapy (DeLLphi-304). N Engl J Med. 2025;[Epub ahead of print]. Doi:10.1056/NEJMoa2502099.
18. Dziadziuszko R, Souquet PJ, Planchard D, Antonia SJ, Reck M, Moro-Sibilot D, et al. ATLANTIS: lurbinectedin/doxorubicin versus investigator's choice in relapsed SCLC—a randomized, phase 3 trial. Lancet Respir Med. 2023;11(12):1133-47. Doi:10.1016/S2213-2600(23)00186-0.
19. Chen R, Gibbons DL, Owonikoko TK, Socinski MA, Haggstrom D, Lyss A, et al. Berzosertib plus Topotecan versus Topotecan alone in relapsed SCLC: randomized phase 2 trial. JAMA Oncol. 2023;9(5):690-8. Doi:10.1001/jamaoncol.2023.0585.
20. Levy A, Tseng YD, Lam TC, et al. Prophylactic cranial irradiation for SCLC—an ASTRO clinical guideline update. J Thorac Oncol. 2025;20(7):e128-36. Doi:10.1016/j.jtho.2025.03.012.
21. Tsui DCC, et al. Adoption and early outcomes of Atezolizumab with Carboplatin/Etoposide after IMpower133. Ann Oncol. 2021;32(Suppl 5):S1011. Doi:10.1016/j.annonc.2021.08.2128.

22. FDA. FDA approves Durvalumab for extensive-stage small cell lung cancer. 2020 Mar 27. Available at: https://www.fda.gov (accessed Aug 15, 2025).
23. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. New England Journal of Medicine. 2024 Oct 10;391(14):1313-27.
24. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Temozolomide plus veliparib in relapsed-sensitive or refractory SCLC: a randomized, double-blind, phase II study. J Clin Oncol. 2018;36(23):2386-94. Doi:10.1200/JCO.2018.77.7672.
25. Dómine Gómez M, Csőszi T, Jaal J, Kudaba I, Nikolov K, Radosavljevic D, et al. Exploratory composite endpoint demonstrates benefit of trilaciclib across components of myeloprotection in SCLC. Int J Cancer. 2021;149(7):1463-72. Doi:10.1002/ijc.33705.
26. Goldschmidt J, Monnette A, Shi P, DeLea T, Kim D, Lage MJ, et al. Real-world outcomes with trilaciclib in extensive-stage SCLC in US community oncology. Adv Ther. 2023;40(1):137-59. Doi:10.1007/s12325-022-02256-0.
27. Scattolin D, Saldan G, Fassan M, Pilotto S, Bria E. The emerging role of SLFN11 in predicting response to DNA-damaging therapy and PARP inhibitors. Cancer Treat Rev. 2024;126:102848. Doi:10.1016/j.ctrv.2024.102848.
28. Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with Temozolomide in SCLC. Clin Cancer Res. 2017;23(2):523-35. Doi:10.1158/1078-0432.CCR-16-1040.